Wilson Asset Management International PTY Ltd. lessened its stake in CME Group Inc. (NASDAQ:CME – Free Report) by 10.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,026 shares of the financial services provider’s stock after selling 5,090 shares during the period. CME Group comprises about 3.0% of Wilson Asset Management International PTY Ltd.’s holdings, making the stock its 12th largest holding. Wilson Asset Management International PTY Ltd.’s holdings in CME Group were worth $12,166,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in the stock. Caldwell Trust Co grew its holdings in CME Group by 116.3% in the 3rd quarter. Caldwell Trust Co now owns 93 shares of the financial services provider’s stock worth $25,000 after acquiring an additional 50 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of CME Group during the third quarter valued at about $27,000. Financial Consulate Inc. purchased a new stake in shares of CME Group during the third quarter worth about $28,000. Sagard Holdings Management Inc. bought a new stake in shares of CME Group in the second quarter worth about $30,000. Finally, Corundum Trust Company INC purchased a new position in CME Group during the 3rd quarter valued at about $30,000. Hedge funds and other institutional investors own 87.75% of the company’s stock.
CME Group Stock Performance
Shares of CME stock opened at $302.27 on Monday. The company’s fifty day moving average price is $276.90 and its 200-day moving average price is $273.00. The stock has a market cap of $109.00 billion, a PE ratio of 27.09, a price-to-earnings-growth ratio of 3.29 and a beta of 0.27. The company has a current ratio of 1.03, a quick ratio of 1.02 and a debt-to-equity ratio of 0.12. CME Group Inc. has a 12 month low of $239.70 and a 12 month high of $302.79.
Analysts Set New Price Targets
CME has been the subject of several research analyst reports. Raymond James Financial dropped their price objective on CME Group from $311.00 to $310.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Rothschild & Co Redburn raised their price target on CME Group from $297.00 to $300.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. UBS Group reissued a “neutral” rating and set a $310.00 price objective on shares of CME Group in a research report on Friday. The Goldman Sachs Group decreased their price objective on shares of CME Group from $265.00 to $264.00 and set a “sell” rating for the company in a report on Wednesday, January 14th. Finally, TD Cowen lifted their target price on shares of CME Group from $305.00 to $328.00 and gave the company a “buy” rating in a research note on Thursday. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $297.47.
Read Our Latest Stock Analysis on CME
Insider Buying and Selling
In related news, Director William R. Shepard purchased 251 shares of CME Group stock in a transaction dated Tuesday, December 30th. The stock was purchased at an average cost of $278.37 per share, for a total transaction of $69,870.87. Following the completion of the acquisition, the director directly owned 258,710 shares of the company’s stock, valued at $72,017,102.70. The trade was a 0.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Terrence A. Duffy sold 25,000 shares of CME Group stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $269.55, for a total value of $6,738,750.00. Following the completion of the transaction, the chief executive officer directly owned 65,804 shares of the company’s stock, valued at approximately $17,737,468.20. This represents a 27.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.30% of the company’s stock.
More CME Group News
Here are the key news stories impacting CME Group this week:
- Positive Sentiment: Q4 earnings beat and commentary reinforced the firm’s resilient fee-based franchise — investors reacted to better-than-expected quarterly results and the company hitting a new one-year high after the report. Earnings Call Transcript
- Positive Sentiment: Deutsche Bank raised its price target to $316 and maintained a buy rating, giving fresh analyst support that can help momentum. Deutsche Bank PT Raise
- Positive Sentiment: Morgan Stanley reiterated a Buy rating, highlighting CME’s defensive, fee-based franchise and structural growth drivers. Morgan Stanley Note
- Neutral Sentiment: RBC nudged its target to $302 (sector perform) — a small technical change that largely preserves prior sentiment. RBC PT Adjustment
- Positive Sentiment: Management confirmed the firm is exploring a CME-issued digital token and tokenized cash pilots (including work with Google), a strategic move that could expand 24/7 crypto/product offerings and new non-trading revenue streams. CME Token Exploration
- Negative Sentiment: CME raised initial and maintenance margins for gold and silver futures (e.g., gold margins to 9% from 8%, silver to 18% from 15%) to manage sharp volatility — measures that can damp trading volume and futures activity in the near term. Margin Hikes
- Negative Sentiment: Pelican Bay Capital reported selling CME in Q4, signaling at least some institutional trimming that could weigh on sentiment if others follow. Institutional Selling
- Negative Sentiment: JPMorgan still carries an underweight rating despite updating its target — a reminder there are pockets of skepticism about valuation and upside. JPMorgan Note
CME Group Company Profile
CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.
The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.
See Also
- Five stocks we like better than CME Group
- The day the gold market broke
- Your Bank Account Is No Longer Safe
- What a Former CIA Agent Knows About the Coming Collapse
- He just nailed another gold prediction …
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME – Free Report).
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.
